Normal and Abnormal Aging and the Brain. Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD

Similar documents
Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Surgery in Individuals Age 65+ Possible Risks. Possible Benefits. Potential Causes of POCD 11/24/2014. What is POCD?

1 in 3 seniors dies with Alzheimer s or another dementia.

Social Security Disability Insurance and young onset dementia: A guide for employers and employees

Autoimmunity and immunemediated. FOCiS. Lecture outline

GE Global Research. The Future of Brain Health

MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

THEORIES OF NEUROLOGICAL AGING AND DEMENTIA

2014 Alzheimer s Disease Facts and Figures

Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial

TABLE OF CONTENTS. Introduction Preventing a Complex Disease Like AD is a Challenge AD Risk Factors We Can t Control...

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease

Copywrite - Eric Freitag, Psy.D., 2012

Freiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.

2016 Programs & Information

Local Clinical Trials

Retinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment

Sandro Sorbi DIPARTIMENTO DI SCIENZE NEUROLOGICHE E PSICHIATRICHE

Introduction. Pathogenesis of type 2 diabetes

Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Stroke & Alzheimer s Disease: An Inflammatory Duo

Long-Term Effects of Drug Addiction

2015 Alzheimer s Disease Facts and Figures

Alzheimer s disease. What is Alzheimer s disease?

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005

Primary Endpoints in Alzheimer s Dementia

What Is Dementia? Type of Dementia

TERMS FOR UNDERSTANDING YOUR TYPE 2 DIABETES. Definitions for Common Terms Related to Type 2 Diabetes

Dementia One Day Essentials 2015

GOING BEYOND RISK REDUCTION: PHYSICAL EXERCISE MAY BE AN EFFECTIVE TREATMENT FOR ALZHEIMER S DISEASE AND VASCULAR DEMENTIA

Depression in Older Persons

Diseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University

Objectives. Evaluation of Memory Loss. Cognitive Impairment. Clinical Questions. Medicare Wellness Visit

Meeting the Needs of Aging Persons. Aging in Individuals with a

Understanding Diabetes

Johns Hopkins Memory & Alzheimer s Treatment Center

Healthy Aging Lab: Current Research Abstracts

If you were diagnosed with cancer today, what would your chances of survival be?

C-Reactive Protein and Diabetes: proving a negative, for a change?

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Is Insulin Effecting Your Weight Loss and Your Health?

DIAPHRAGM. DIAgnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma

Clinical Trials of Disease Modifying Treatments

Alzheimer s disease and diabetes

NCRAD. Silver Alert System. Keeping Persons with AD Safe SILVER ALERT:

2016 ALZHEIMER S DISEASE FACTS AND FIGURES

How To Write Long Term Care Insurance

Registered Charity No: Caring for those with a rare, complex and lifelong disease

Improving cardiometabolic health in Major Mental Illness

RESEARCHERS REPORT NEW WAYS TO PREDICT THE DEVELOPMENT OF ALZHEIMER S DISEASE

PHYSICAL ACTIVITY FOR BRAIN HEALTH AND FIGHTING DEMENTIA

ITT Advanced Medical Technologies - A Programmer's Overview

NEUROIMAGING in Parkinsonian Syndromes

Biomarkers for Alzheimer's Disease in Down Syndrome

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

J/601/2874. This unit must be assessed in accordance with Skills for Care and Development s QCF Assessment Principles.

Title: Answers to 5 Common Questions About Texas Health Insurance. Word Count: 545

Introduction To The Zone

GYMR A4 Study Long Form Film

Alzheimer s & Dementia 7 (2011)

Preventing Alzheimer s Disease What Do We Know?

Activity 4 Long-Term Effects of Drug Addiction

Chickenpox and Shingles Vaccines

GloP1r - A New Frontier in Exercise and Nutrition

Blood Testing Protocols. Disclaimer

Electronic Medical Records and Genomics: Possibilities, Realities, Ethical Issues to Consider

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012

HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE

How small things get big

1333 Plaza Blvd, Suite E, Central Point, OR *

Understanding the Genetics of FTD

How To Find Out If The Gulf War And Health Effects Of Serving In The Gulf Wars Are Linked To Health Outcomes

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

Big Data for Population Health

Electrohypersensitivity and multiple chemical sensitivity: two clinicbiological. disorder?

Dealing with Cognitive Impairment in the Patient with Breast Cancer

INSIGHT Newsletter of the USC Alzheimer Disease

Do You Know the Health Risks of Being Overweight?

Participating in Alzheimer s Disease Clinical Trials and Studies

Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions

Diabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.

Management in the pre-hospital setting

Chapter 10. Summary & Future perspectives

In this chapter we will review some of the evidence of the critical

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA PhD STUDIES SCHOOL. PhD THESIS - ABSTRACT -

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Targeting brain inflammation to treat methamphetamine addiction

2011 Alzheimer s Disease Facts and Figures

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Group Benefits Evidence of Insurability for Comprehensive Optional Critical Illness Insurance

OHTAC Recommendation

Is there a Distinct Phenotype to Memory Loss in Alzheimer's Disease?

Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE

Cognitive Testing for Underwriting Life Insurance

Transcription:

Normal and Abnormal Aging and the Brain Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD

The myth of cognitive decline

The myth of cognitive decline

Individual change varies

Individual change varies

Cognitive aging trajectories

Take home points Decline in cognition with age and brain is not inevitable; there is considerable variability in how much and how fast Age-related declines in cognition and brain structure and function are the result of pathological processes The better we understand these processes, the better equipped we are do something about it

Vision Annual wellness visits will include cognitive test results, structural and molecular neuroimaging, proteomics, vascular and other risks, health-related behaviors, and genomic profile. This information will identify risks for current and future problems with brain structure or function and lead to targeted, patient-specific interventions.

UCSF cohort Over 850 functionally intact, community dwelling older subjects 365 active in longitudinal studies Comprehensive evaluations: Cognitive, neurologic and functional assessment DNA Banked serum, plasma, whole blood, lymphocytes MRI: structural, DTI, resting state, ASL PET scans CSF

Genetics Health and Exposures Lifestyle Cerebrovascular risk factors Oxidative stress Inflammation Proteins Cortical grey matter White matter Hippocampal volume APOE Klotho Dopamine receptors Seritonin receptors Processing Speed Executive, language, & spatial skills Episodic Memory

Klotho: aging regulator and cognitive enhancer KLOTHO (KL) Transmembrane protein; hormone Circulates throughout body, brain AMPA and NMDA receptors; insulin response KLOTHO (KL): F352V and C370S ( KL-VS ) 20-25% heterozygosity 1.6x increase in protein levels Longevity; protection against age-related disease Cognitive enhancement in aging humans

Variation in Longevity Gene KLOTHO is Associated with Greater Cognition and Cortical Volumes in Aging Jennifer Yokoyama and Dena Dubal

Protective KL-VS genotype Carrying 1 copy of KL-VS is associated with better executive function in two healthy aging cohorts This occurs independent of age

Protective KL-VS genotype Greater volume in a relevant brain region Carrying 1 copy of KL-VS is associated with greater volume in right DLPFC in two healthy aging cohorts This occurs independent of age

Neurodegenerative diseases Protein Amyloid and tau Alpha-synuclein Tau TDP-43 Clinical syndrome Alzheimer s disease Parkinson s and Lewy body disease Behavioral variant FTD Progressive aphasia (non-fluent) Progressive supranuclear palsy Corticobasal degeneration Behavioral variant FTD Progressive aphasia (semantic) ALS (Lou Gehrig s disease)

Cog normal: low amyloid Cog normal: intermediate amyloid Cog normal: high amyloid Alzheimer s disease DVR 2.5 0.4

Implications Some of the cognitive changes that we associate with aging could very well reflect underlying, accumulation of abnormally folded proteins

Cerebrovascular disease

Predicting executive functioning: Insulin resistance β p-value Age -.31.00 Education.12.19 Gender -.11.20 LDL.12.18 BMI.11.34 MAP -.07.45 WMH -.24.02 HOMA-IR -.25.02 Frazier et al., 2015

Predicting executive functioning: Triglycerides β p-value Age -0.16 0.04 Education 0.24 0.00 Gender 0.10 0.16 LDL -0.03 0.36 ApoE4 Status -0.62 0.54 CDR -0.30 0.00 Global FA -0.03 0.71 Triglycerides -0.20 0.01 Parthasarathy, 2015

The neuroinflammation story Inflammation is a normal response to injury Peripheral injury rapidly leads to an inflammatory response in the brain This inflammatory response is adaptive as long as the inflammation subsides

Aging and Immunosenescence Degradation of immune system with advancing aging Increased susceptibility to disease and infection Up-regulation of inflammatory responses Result: Low-grade, chronic systemic proinflammatory state.

Inflammation and white Looked at CRP, TNF-α, and IL-6 Detectable levels of inflammatory markers were related to lower white matter integrity This relationship is more pronounced with age matter

Response Latency Z-score What can super-agers We can reliably measure declines in processing speed over 2-3 years Studying the extremes of this variability can offer valuable clues about mechanisms teach us? 4.5 3.5 2.5 1.5 0.5 Processing Speed T1 Processing Speed T2 Elite-agers Average-agers Sub-agers

Results No groups differences were found in BMI, cholesterol, or APOE genotype.

Cardiorespiratory fitness We can estimate cardiorespiratory fitness using measures of physical activity, BMI, and heart rate

Better white matter integrity

Lower inflammation

Summary Aging significantly impacts brain structure & function, but these changes are neither universal nor inevitable Multiple factors influence how the brain changes with age, some of which are under our control, and some may be modifiable in the future A better understand of these factors can lead to more successful cognitive aging